Norden Group LLC sells 1,503 shares of Hologic, Inc. (NASDAQ:HOLX)

Norden Group LLC reduced its holdings in Hologic, Inc. (NASDAQ:HOLX – Free Report ) by 27.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,977 shares of the medical equipment provider’s stock after selling 1,503 shares during the period. Norden Group LLC’s holdings in Hologic were worth $295,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have recently made changes to their positions in HOLX. Price T Rowe Associates Inc. MD boosted its holdings in Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after buying an additional 2,753,016 shares during the last quarter. Norges Bank bought a new stake in shares of Hologic during the fourth quarter valued at about $217,529,000. BNP PARIBAS ASSET MANAGEMENT Holding SA increased its holdings in shares of Hologic by 4.0% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding SA now owns 2,271,603 shares of the medical equipment provider’s stock worth $168,666,000 after acquiring an additional 87,176 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Hologic by 117.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock valued at $154,598,000 after acquired an additional 1,168,564 shares in the last quarter. Finally, TD Asset Management Inc raised its stake in Hologic by 2.0% in the 1st quarter. TD Asset Management Inc now owns 1,934,841 shares of the medical equipment provider’s stock valued at $150,840,000 after buying an additional 37,136 shares during the last quarter. 94.73% of shares are held by institutional investors and hedge funds.

Analysts on Wall Street are forecasting an increase

Several analysts recently commented on HOLX shares. Stephens reissued an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 10th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $82.00 price objective on shares of Hologic in a report on Friday, August 16th. Evercore ISI boosted their target price on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. upped their target price on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.60, based on data from MarketBeat.com.

Get the latest research report on Hologic

Insider trading at Hologic

In related news, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Stephen P. Macmillan sold 3,672 shares of the business’s stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the sale, the chief executive officer now directly owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC’s website. Also, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,280 shares of company stock worth $1,469,973. 1.75% of shares are owned by company insiders.

Hologic Stock by 1.4%

HOLX opened at $82.69 on Tuesday. Hologic, Inc. has a 12-month low of $64.02 and a 12-month high of $84.67. The company’s 50-day moving average price is $79.62, and its two-hundred-day moving average price is $76.70. The stock has a market cap of $19.21 billion, a price-to-earnings ratio of 42.19, a PEG ratio of 2.58 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99, and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX – Get Your Free Report ) last released its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, topping the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. In the same quarter last year, the company earned $0.93 per share. Hologic’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, equities analysts expect Hologic, Inc. to post 4.09 earnings per share for the current year.

Hologic Company Profile

(Free report)

Hologic, Inc develops, manufactures and supplies diagnostic products, medical imaging systems and surgical products for women’s health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgery and Skeletal Health. Offers Aptima molecular diagnostic tests to detect infectious microorganisms; Aptima viral load tests for hepatitis B virus, hepatitis C virus, human immunodeficiency virus, and human cytomegalovirus; Aptima Bacterial Vaginosis and Candida Vaginitis Tests for Vaginitis Diagnosis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 tests to detect SARS-CoV-2; ThinPrep System for cytology applications; and the rapid fetal fibronectin test that helps doctors assess the risk of preterm birth.

Featured stories

Get news and reviews for Hologic Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Hologic and related companies with MarketBeat.com’s FREE daily email newsletter.